LOOK WHO’S SELLING NTMD
The company’s chief medical officer exercised options to buy 60,000 shares last week at $1.16 and sold them for $21.94. In December, he sold 30,000 shares at $20.63 that he had acquired by exercising options at 8 cents a share. Meanwhile, the company itself has filed a ‘shelf registration’ to sell up to a quarter billion dollars worth of its stock and/or bonds – not an insignificant sum for a company this size.
Neither of these pieces of information is ‘dispositive,’ as they say – ‘finally determinative.’ But taken with the IMS prescription data suggesting that only a few hundred prescriptions for BiDil may have been written thus far (while expenses of more than $100 million for the year have been budgeted), one imagines that the chief medical officer, and the company, may be on to a good thing.
(A shelf registration doesn’t require a company to issue new securities, but puts it in a position to do so without regulatory delay.)
The stock closed last night at $19.90, for an overall market valuation, with just over 30 million shares outstanding, of $600 million.
Anything’s possible, but . . . don’t sell your puts.
BEFORE WE ATTACK IRAN . . .
The author argues that it’s a serious situation, but hardly a crisis.
Quote of the Day
The teacher affects eternity. He can never tell where his influence stops.~Henry Adams
Request email delivery
- Mar 22:
- Mar 21:
None Of Us Is Home . . .
- Mar 20:
The Minister of Happiness Will See You Now
- Mar 17:
Flying To Cuba And Ireland Without A Tug Made In CHAYYY-na
- Mar 15:
Eerie Echoes of the Civil War
- Mar 14:
That $1,000 Bonus? It Was Really $190
- Mar 13:
- Mar 12:
Credit Where It’s Due
- Mar 9:
How To Win The Lottery
- Mar 8:
- Mar 22: